atopic dermatitis (AD) eczema
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: age 18-70 years AD positive APT during previous study (NL32336.041.10 or 10-161 METC UMCU) and local TSLP mRNA (qPCR) and protein expression (immunohistochemistry) detectable in skinbiopsy material from testsite.
Exclusion criteria
Exclusion criteria: - Active AD on the back - LSS >30 - Not sensitized to aeroallergens, such as house dust mite (demonstrated by a positive Immuno CAP test for these allergens). - Treatment with systemic corticosteroid or other immunosuppressive medication (such as cyclosporin) within the 4 weeks prior to having the biopsies performed. In addition, weekly use of equal or more than 50 grams of topical corticosteroids class IV or weekly use of equal or more than 100 grams of topical corticosteroids class III. - Treatment of the biopsy and APT regions not restricted to indifferent topical treatment in the 2 weeks prior - Exposure of biopsy location to UV sunlicht (e.g. UV-therapy, sunny holiday) in the 2 weeks prior to taking biopsies. - Use of coumarin derivatives - Use of antihistamines in the week or days before and during the APT (see patientinformation 'Bijlage 4: Medicatielijst').
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In vivo: TSLP mRNA expression level (qPCR or quantitative Polymerase Chain Reaction) in cryosections from skin biopsy material (quantitative). | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunohistochemical staining for TSLP protein and other related products in cryosections from skin biopsy material (qualitative; determining presence and localization). | — |
Countries
Netherlands
Outcome results
None listed